| Abstrakt: |
• Ghezzi A received honoraria for speaking from Biogen-Idec, Merck-Serono, Novartis, Genzyme, Teva, and Allergan, and for consultancy from Merck-Serono, Teva, Novartis, and Biogen-Idec, and received support for participation in National and International Congresses from Schering, Biogen-Idec, Merck-Serono, Novartis, Genzyme, and Teva. • Landi D received travel funding from Biogen, Merck Serono, Sanofi-Genzyme and Teva, honoraria for speaking from Sanofi-Genzyme and Teva, and consultation fees from Merck Serono and Teva. • Portaccio E served on scientific advisory board for Biogen Idec and Merck Serono, received honoraria for speaking and funding for traveling from Biogen, Genzyme, Novartis, Merck, and Teva, and received research support from Merck Serono. Dr Kim reports personal fees from Bayer Schering Pharma, Biogen, Eisai, HanAll BioPharma, MedImmune/Viela Bio, Merck Serono, and Novartis; grants and personal fees from Sanofi Genzyme, Teva-Handok, and UCB; grants from Ministry of Science and ICT; and other financial relationships (Associate Editor/Co-Editor) with Multiple Sclerosis Journal-Experimental, Translational and Clinical, and Journal of Clinical Neurology. [Extracted from the article] |
